Injection of recombinant IFNγ was tried in several anti-tumor clinical trials including chronic myelogenous leukemia (30), bladder carcinoma (31), ovarian cancer (32), adult T cell leukemia (29) and melanoma (33), but the results were mixed. This evidence concerns the gene IFNG and adult T-cell leukemia/lymphoma.